Trial Search Results

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Biological: Ipilimumab
  • Biological: Nivolumab
  • Biological: Sargramostim

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   - Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1

   - Patients must have known BRAF mutational status of tumor; wild-type (WT) or mutated,
   prior to randomization

   - Women of childbearing potential and sexually active males must be strongly advised to
   use an accepted and effective method of contraception or to abstain from sexual
   intercourse for at least one week prior to the start of the research study, and
   continuing for 5 months for women of childbearing potential and 7 months for sexually
   active males after the last dose of the study drugs

   - Patients must have unresectable stage III or stage IV melanoma; patients must have
   histological or cytological confirmation of melanoma that is metastatic or
   unresectable and clearly progressive

   - Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease
   must be evaluated within 4 weeks prior to randomization

   - Patients may have had prior systemic therapy in the adjuvant setting (e.g. interferon,
   BRAF, or mitogen-activated protein kinase [MEK] agents); patients may have had prior
   anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the adjuvant setting, if at least
   one year from last dose of treatment has passed prior to beginning treatment; patients
   may not have had any prior programmed cell death (PD)-1/PD-ligand (PD-L)1 agent in the
   adjuvant setting

   - Patients must have discontinued chemotherapy, immunotherapy or other investigational
   agents used in the adjuvant setting >= 4 weeks prior to randomization and recovered
   from adverse events due to those agents; mitomycin and nitrosoureas must have been
   discontinued at least 6 weeks prior to entering the study; patients must have
   discontinued radiation therapy >= 2 weeks prior to entering the study and recovered
   from any adverse events associated with treatment; prior surgery must be >= 4 weeks
   from randomization and patients must be fully recovered from post-surgical
   complications

   - White blood count >= 3,000/uL (obtained within 4 weeks prior to randomization)

   - Absolute neutrophil count (ANC) >= 1,500/uL (obtained within 4 weeks prior to
   randomization)

   - Platelet count >= 100,000/uL (obtained within 4 weeks prior to randomization)

   - Hemoglobin >= 9 g/dL (obtained within 4 weeks prior to randomization)

   - Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance
   (CrCl) >= 40 ml/min (obtained within 4 weeks prior to randomization)

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x
   ULN for patients with documented liver metastases) (obtained within 4 weeks prior to
   randomization)

   - Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement
   and =< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks
   prior to randomization)

   - Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those
   with known Gilbert's syndrome (obtained within 4 weeks prior to randomization)

   - Serum lactate dehydrogenase (LDH) =< 10 X ULN (obtained within 4 weeks prior to
   randomization)

   - Patients with autoimmune hypothyroid disease or type I diabetes on replacement
   treatment are eligible

Exclusion Criteria:

   - Women must not be pregnant or breast-feeding due to use of cytotoxic immunotherapy and
   risk of teratogenic side effects; all females of childbearing potential must have a
   blood test or urine study within 2 weeks prior to randomization to rule out pregnancy;
   a female of childbearing potential is any woman, regardless of sexual orientation or
   whether they have undergone tubal ligation, who meets the following criteria: 1) has
   not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
   postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in
   the preceding 24 consecutive months)

   - Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the
   metastatic setting

   - Patients must not receive any other investigational agents while on study or within
   four weeks prior to randomization

   - Patients are excluded for receiving any non-oncology vaccine therapy used for
   prevention of infectious diseases for up to four weeks (28 days) prior to or after any
   dose of ipilimumab; NOTE: Patients are permitted to receive inactivated vaccines and
   any non live vaccines including those for the seasonal influenza and coronavirus
   disease 19 (COVID-19)

   - Patients are ineligible if they have any currently active central nervous system (CNS)
   metastases; patients who have treated brain metastases (with either surgical resection
   or stereotactic radiosurgery) that have been stable on head magnetic resonance imaging
   (MRI) or contrast computed tomography (CT) scan for at least 4 weeks following
   treatment and within 4 weeks prior to randomization are eligible; patients must not
   have taken any steroids =< 14 days prior to randomization for the purpose of managing
   their brain metastases; patients with only whole brain irradiation for treatment of
   CNS metastases will be ineligible

   - Patients must not have other current malignancies, other than basal cell skin cancer,
   squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in
   situ of the breast; patients with other malignancies are eligible if they have been
   continuously disease-free for > 3 years prior to the time of randomization

   - Patients must not have any serious or unstable pre-existing medical conditions (aside
   from malignancy exceptions specified above), including but not limited to, ongoing or
   active infection requiring parenteral antibiotics on day 1, history of bleeding
   diathesis or need for concurrent anticoagulation (international normalized ratio [INR]
   =< 1.5 and partial thromboplastin time [PTT] within 1.1 x ULN), or psychiatric
   illness/social situations that would limit compliance with study requirements,
   interfere with subject's safety, or obtaining informed consent

   - Patients with human immunodeficiency virus (HIV) infection are ineligible; due to the
   mechanism of action of ipilimumab and GM-CSF, activity and side effects in an immune
   compromised patient are unknown

   - Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV)
   infection are not eligible; patients with cleared HBV and HCV (0 viral load) infection
   will be allowed

   - Patients must not have autoimmune disorders or conditions of immunosuppression that
   require current ongoing treatment with systemic corticosteroids (or other systemic
   immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or
   continuous use of topical steroid creams or ointments or ophthalmologic steroids; a
   history of occasional (but not continuous) use of steroid inhalers is allowed;
   replacement doses of steroids for patients with adrenal insufficiency are allowed;
   patients who discontinue use of these classes of medication for at least 2 weeks prior
   to randomization are eligible if, in the judgment of the treating physician
   investigator, the patient is not likely to require resumption of treatment with these
   classes of drugs during the study

   - Exclusion from this study also includes patients with a history of symptomatic
   autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis
   [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis
   [e.g., Wegener's granulomatosis]); motor neuropathy considered of autoimmune origin
   (e.g., Guillain-Barre syndrome and myasthenia gravis); other CNS autoimmune disease
   (e.g., multiple sclerosis)

   - Patients must not have a history of inflammatory bowel disease or diverticulitis
   (history of diverticulosis is allowed)

   - Patients must not have other significant medical, surgical, or psychiatric conditions
   or require any medication or treatment that in the opinion of the investigator may
   interfere with compliance, make the administration of the study drugs hazardous or
   obscure the interpretation of adverse events (AEs), such as a condition associated
   with frequent diarrhea; patients must not have an active infection requiring current
   treatment with parenteral antibiotics

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting